Temessadouno Fara Wagbo, Ndong Jean Gilbert, Gignoux Etienne, Coppieters Yves, Ba Alhassane, Sidibe Youssouf Diam, Daou Aminata, Malou Nada, Compaore Idrissa, Fane Tidiani, Simons Erica, Luquero Francisco, Mills Clair, Vuti Komla Mawunya, Nkokolo Massamba Marie Hortense, Guiramand Sonia
Médecins Sans Frontières, Dakar, Senegal.
Épicentre, Paris, France.
PLOS Glob Public Health. 2023 Jan 5;3(1):e0001316. doi: 10.1371/journal.pgph.0001316. eCollection 2023.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus associated with coronavirus disease (COVID-19). At the time of the study, little data on the level of exposure of the population in Koutiala district in Mali to SARS-CoV-2 was available. Although blood donors are not representative of the general population, a COVID-19 seroprevalence estimate in this population was intended to assess the extent of community transmission, serve as a health alert system, and help guide the public health response. We measured seroprevalence of anti-SARS-CoV-2 antibodies using NG-Biotech SARS-Cov-2 RDT and ECLIA test between January and June 2020. This is a cross-sectional study of volunteer blood donors aged 18 to 60 years, independent of any previous COVID-19 disease. A stratified analysis of seroprevalence by month of sample collection and a comparison of the results of the NG-Biotech SARS-Cov-2 RDT with those of the ECLIA test was performed. The overall prevalence of antibodies to SARS-Cov-2 virus assessed by the NG-Biotech SARS-Cov-2 RDT was 24.6% (95% CI 21.8-27.4) and by the ECLIA test was 70.2 (95% CI 64.9-75.5). Both estimates remained relatively stable over the study period. We observed SARS-CoV-2 exposure much higher than indicated by case-based surveillance. The national surveillance system, as it was, was not able to detect variations in incidence, and as such, we do not recommend it as an alert system. However, the discrepancy between the results of the rapid test and the ECLIA test shows that further research is required to assess the validity of these test before a more solid conclusion can be drawn it their use in surveillance.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是与冠状病毒病（COVID-19）相关的病毒。在本研究开展时，关于马里库蒂亚拉区人群接触SARS-CoV-2的水平的数据很少。尽管献血者不能代表一般人群，但对该人群进行COVID-19血清流行率估计旨在评估社区传播程度、作为健康警报系统并帮助指导公共卫生应对措施。我们在2020年1月至6月期间使用NG-Biotech SARS-CoV-2快速诊断检测和电化学发光免疫分析检测来测量抗SARS-CoV-2抗体的血清流行率。这是一项针对18至60岁志愿献血者的横断面研究，这些献血者与之前的任何COVID-19疾病无关。我们按样本采集月份对血清流行率进行了分层分析，并将NG-Biotech SARS-CoV-2快速诊断检测结果与电化学发光免疫分析检测结果进行了比较。通过NG-Biotech SARS-CoV-2快速诊断检测评估的SARS-CoV-2病毒抗体总体流行率为24.6%（95%置信区间21.8 - 27.4），通过电化学发光免疫分析检测评估的为70.2%（95%置信区间64.9 - 75.5）。在研究期间，这两个估计值都保持相对稳定。我们观察到SARS-CoV-2暴露水平远高于基于病例的监测所显示的水平。当时的国家监测系统无法检测发病率的变化，因此，我们不建议将其作为警报系统。然而，快速检测结果与电化学发光免疫分析检测结果之间的差异表明，在更确凿地得出它们在监测中的使用结论之前，需要进一步研究以评估这些检测的有效性。
